InflammX Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5.75M

  • Investors
  • 4

InflammX General Information

Description

Developer of an orally administered compound designed to inhibit the dysregulated inflammasome pathway of autoinflammation. The company's product offers disease modification by inhibiting the pathway by normalizing prematurely open pathological hemichannels in the cell membrane that release into the extracellular space, which is a signal for activation and release of multiple proinflammatory cytokines, helping healthcare providers to treat diabetic macular edema, macular degeneration, and chronic kidney diseases.

Contact Information

Formerly Known As
CoDa Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 275 Bayshore Boulevard
  • Unit 1607
  • Tampa, FL 33606
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 275 Bayshore Boulevard
  • Unit 1607
  • Tampa, FL 33606
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InflammX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 01-Feb-2025 $5.75M Completed Clinical Trials - Phase 2
8. Later Stage VC 19-Nov-2021 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B1) 12-Jan-2021 Completed Clinical Trials - Phase 2
6. Secondary Transaction - Private 01-Jan-2019 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 20-May-2014 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 24-Jul-2012 Completed Startup
3. Debt - General 06-Oct-2011 Completed Startup
2. Early Stage VC (Series A) 08-Oct-2008 $23.2M $23.2M Completed Startup
1. University Spin-Out 01-Jan-2005 Completed Startup
To view InflammX’s complete valuation and funding history, request access »

InflammX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series A-1
To view InflammX’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

InflammX Patents

InflammX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250352508-A1 Prevention and treatment of post-acute infection syndromes Pending 14-May-2024
WO-2025240654-A1 Prevention and treatment of post-acute infection syndromes Pending 14-May-2024
CA-3212378-A1 Compositions and methods for modulating epithelial-mesenchymal transition Pending 02-Mar-2021
EP-4301381-A1 Compositions and methods for modulating epithelial-mesenchymal transition Pending 02-Mar-2021
EP-4301381-A4 Compositions and methods for modulating epithelial-mesenchymal transition Pending 02-Mar-2021 A61K31/352
To view InflammX’s complete patent history, request access »

InflammX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InflammX Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
ExSight Ventures Venture Capital Minority
Auckland UniServices Corporate Venture Capital Minority
Aspire NZ Seed Fund Venture Capital Minority
University of London University
To view InflammX’s complete investors history, request access »

InflammX FAQs

  • When was InflammX founded?

    InflammX was founded in 2005.

  • Where is InflammX headquartered?

    InflammX is headquartered in Tampa, FL.

  • What is the size of InflammX?

    InflammX has 4 total employees.

  • What industry is InflammX in?

    InflammX’s primary industry is Drug Discovery.

  • Is InflammX a private or public company?

    InflammX is a Private company.

  • What is InflammX’s current revenue?

    The current revenue for InflammX is .

  • How much funding has InflammX raised over time?

    InflammX has raised $97.7M.

  • Who are InflammX’s investors?

    ExSight Ventures, Auckland UniServices, Aspire NZ Seed Fund, and University of London have invested in InflammX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process